Johnson & Johnson (NYSE:JNJ) Given New $255.00 Price Target at Royal Bank Of Canada

Posted by Defense World Staff on Feb 4th, 2026

Johnson & Johnson (NYSE:JNJ – Free Report) had its price objective increased by Royal Bank Of Canada from $240.00 to $255.00 in a research report released on Tuesday morning, Marketbeat.com reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages have also weighed in on JNJ. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Wednesday, January 28th. TD Cowen lifted their price objective on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Raymond James Financial lifted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Finally, Argus increased their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Read Our Latest Research Report on JNJ

Johnson & Johnson Trading Up 1.0%

Shares of JNJ opened at $233.11 on Tuesday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $235.20. The stock has a fifty day moving average of $211.74 and a two-hundred day moving average of $192.73. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $561.62 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 2.24 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. During the same quarter in the previous year, the business earned $2.04 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds have recently bought and sold shares of the company. EWA LLC raised its stake in Johnson & Johnson by 9.3% during the fourth quarter. EWA LLC now owns 3,217 shares of the company’s stock valued at $666,000 after buying an additional 273 shares in the last quarter. NewEdge Wealth LLC lifted its stake in Johnson & Johnson by 10.1% during the fourth quarter. NewEdge Wealth LLC now owns 259,718 shares of the company’s stock worth $53,749,000 after purchasing an additional 23,771 shares during the last quarter. Denali Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.5% in the 4th quarter. Denali Advisors LLC now owns 3,282 shares of the company’s stock valued at $679,000 after buying an additional 49 shares during the period. LJI Wealth Management LLC boosted its stake in Johnson & Johnson by 4.4% in the fourth quarter. LJI Wealth Management LLC now owns 5,683 shares of the company’s stock valued at $1,176,000 after acquiring an additional 238 shares during the period. Finally, Ballentine Partners LLC grew its stake in Johnson & Johnson by 2.3% during the 4th quarter. Ballentine Partners LLC now owns 55,854 shares of the company’s stock worth $11,559,000 after buying an additional 1,261 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Multiple analyst upgrades and higher price targets — Morgan Stanley upgraded JNJ to Overweight and raised its PT to $262, RBC lifted its PT to $255 with an Outperform rating, BofA nudged its PT to $227, and other outlets report a PT raised to $265; these moves signal stronger analyst conviction on JNJ’s earnings and margin outlook. Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 RBC Raises Price Target on Johnson & Johnson to $255 BofA lifts PT on Johnson & Johnson (JNJ) to $227 from $221 – here’s why Johnson & Johnson (NYSE:JNJ) Price Target Raised to $265.00
Positive Sentiment: MedTech/product progress: J&J MedTech announced updates to its Varipulse product and a new ultrasound catheter, which can expand procedure use and revenue potential in vascular/interventional markets. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter
Positive Sentiment: Commercial rollout: J&J launched the first daily-disposable multifocal toric contact lens for astigmatic presbyopic patients in the U.K. and Ireland (ACUVUE®), supporting the consumer/vision revenue stream. Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia
Positive Sentiment: Investor access: Management will present at the TD Cowen Health Care Conference on March 3 — a chance to hear updated guidance, pipeline milestones and margin drivers directly from management. Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
Neutral Sentiment: Context piece: A Forbes analysis reviews JNJ’s ~52% run over the past nine months, attributing gains to improved earnings, product wins and legal progress — useful background but not an immediate catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.